NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells

Area of Science:

• Oncology
• Pediatric Neuro-oncology
• Cancer Stem Cell Biology

Background:

• Medulloblastoma (MB) is the most common pediatric malignant brain tumor with significant morbidity and recurrence risks.
• Neuropilin-1 receptor (NRP1) is implicated in MB progression, and its inhibition promotes cancer stem cell differentiation.
• Targeting NRP1 presents a potential strategy to improve current medulloblastoma treatments.

Purpose of the Study:

• To evaluate the efficacy of NRP1 inhibition using MR438 in combination with radiotherapy (RT) for medulloblastoma.
• To assess the impact of this combination therapy on medulloblastoma cancer stem cells both in vitro and in vivo.

Main Methods:

• NRP1 inhibition was achieved using the peptidomimetic agent MR438.
• Experiments were conducted on medulloblastoma cell lines (DAOY, D283-Med, D341-Med) in vitro and in vivo xenograft models (heterotopic and orthotopic).
• Evaluations included radiosensitization of cancer stem-like cells, tumor growth, mouse survival, and clonogenic assays.

Main Results:

• MR438 demonstrated radiosensitization of medulloblastoma stem-like cells in vitro.
• Combination therapy with MR438 and RT improved tumor growth and survival in heterotopic models.
• Significant reduction in cancer stem cells was observed with the combination treatment.
• A therapeutic benefit was noted in orthotopic models at a lower radiation dose (10 Gy) but not at a higher dose (20 Gy).

Conclusions:

• Targeting NRP1 with MR438 is a promising strategy to limit medulloblastoma progression.
• The combination therapy effectively decreases the number of medulloblastoma stem cells.
• This approach may allow for a reduction in the radiation dose required for effective treatment.